156 related articles for article (PubMed ID: 37314979)
1. Diabetes, metformin use, and survival in esophageal cancer: a population-based cohort study.
Wang QL; Santoni G; Lagergren J
JNCI Cancer Spectr; 2023 Jul; 7(4):. PubMed ID: 37314979
[TBL] [Abstract][Full Text] [Related]
2. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Bowker SL; Majumdar SR; Veugelers P; Johnson JA
Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
[TBL] [Abstract][Full Text] [Related]
3. Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study.
Calip GS; Yu O; Elmore JG; Boudreau DM
Cancer Causes Control; 2016 May; 27(5):709-20. PubMed ID: 27053250
[TBL] [Abstract][Full Text] [Related]
4. Associations between diabetes medication use and risk of second breast cancer events and mortality.
Calip GS; Yu O; Hoskins KF; Boudreau DM
Cancer Causes Control; 2015 Aug; 26(8):1065-77. PubMed ID: 25956271
[TBL] [Abstract][Full Text] [Related]
5. Improved prognosis in gastric adenocarcinoma among metformin users in a population-based study.
Zheng J; Santoni G; Xie SH; Lagergren J
Br J Cancer; 2021 Jul; 125(2):277-283. PubMed ID: 33972744
[TBL] [Abstract][Full Text] [Related]
6. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
[TBL] [Abstract][Full Text] [Related]
7. Association Between Metformin Use and Risk of Esophageal Squamous Cell Carcinoma in a Population-Based Cohort Study.
Wang QL; Santoni G; Ness-Jensen E; Lagergren J; Xie SH
Am J Gastroenterol; 2020 Jan; 115(1):73-78. PubMed ID: 31821177
[TBL] [Abstract][Full Text] [Related]
8. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Haring A; Murtola TJ; Talala K; Taari K; Tammela TL; Auvinen A
Scand J Urol; 2017 Feb; 51(1):5-12. PubMed ID: 28084175
[TBL] [Abstract][Full Text] [Related]
9. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.
Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S
Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677
[TBL] [Abstract][Full Text] [Related]
11. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure.
Bowker SL; Yasui Y; Veugelers P; Johnson JA
Diabetologia; 2010 Aug; 53(8):1631-7. PubMed ID: 20407744
[TBL] [Abstract][Full Text] [Related]
12. Aspirin or statin use in relation to survival after surgery for esophageal cancer: a population-based cohort study.
Holmberg D; Gottlieb-Vedi E; Hedberg J; Lindblad M; Mattsson F; Lagergren J
BMC Cancer; 2023 Apr; 23(1):375. PubMed ID: 37098462
[TBL] [Abstract][Full Text] [Related]
13. Sex differences in the prognosis after surgery for esophageal squamous cell carcinoma and adenocarcinoma.
Kauppila JH; Wahlin K; Lagergren P; Lagergren J
Int J Cancer; 2019 Mar; 144(6):1284-1291. PubMed ID: 30168595
[TBL] [Abstract][Full Text] [Related]
14. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma.
Rieken M; Xylinas E; Kluth L; Crivelli JJ; Chrystal J; Faison T; Lotan Y; Karakiewicz PI; Sun M; Fajkovic H; Babjuk M; Bachmann A; Scherr DS; Shariat SF
Urol Oncol; 2014 Jan; 32(1):49.e7-14. PubMed ID: 24140245
[TBL] [Abstract][Full Text] [Related]
15. The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death.
Yu OH; Yin H; Azoulay L
Can J Diabetes; 2015 Oct; 39(5):383-9. PubMed ID: 25840943
[TBL] [Abstract][Full Text] [Related]
16. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin.
Evans JM; Ogston SA; Emslie-Smith A; Morris AD
Diabetologia; 2006 May; 49(5):930-6. PubMed ID: 16525843
[TBL] [Abstract][Full Text] [Related]
17. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study.
Douros A; Dell'Aniello S; Yu OHY; Filion KB; Azoulay L; Suissa S
BMJ; 2018 Jul; 362():k2693. PubMed ID: 30021781
[TBL] [Abstract][Full Text] [Related]
18. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study.
Andersson C; Olesen JB; Hansen PR; Weeke P; Norgaard ML; Jørgensen CH; Lange T; Abildstrøm SZ; Schramm TK; Vaag A; Køber L; Torp-Pedersen C; Gislason GH
Diabetologia; 2010 Dec; 53(12):2546-53. PubMed ID: 20838985
[TBL] [Abstract][Full Text] [Related]
19. The Risk of TB in Patients With Type 2 Diabetes Initiating Metformin vs Sulfonylurea Treatment.
Pan SW; Yen YF; Kou YR; Chuang PH; Su VY; Feng JY; Chan YJ; Su WJ
Chest; 2018 Jun; 153(6):1347-1357. PubMed ID: 29253553
[TBL] [Abstract][Full Text] [Related]
20. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
Berkowitz SA; Krumme AA; Avorn J; Brennan T; Matlin OS; Spettell CM; Pezalla EJ; Brill G; Shrank WH; Choudhry NK
JAMA Intern Med; 2014 Dec; 174(12):1955-62. PubMed ID: 25347323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
